Retina 2007 (page 5)

Article

blah

1, 2, 3, 4, 5

2008: the year for combining approaches?
So what do our experts think awaits us in 2008? Will we see combination therapy overtake anti-VEGF monotherapy as a treatment of choice in the treatment of AMD? Will we see the launch of even better instrumentation for vitreoretinal surgery? Will the manufacturers of imaging devices surprise us with a more superior technology?

"Hageman in 2001,3 showed that proteins associated with inflammation and immune-mediated processes are prevalent among drusen-associated constituents and one of the best available markers of AMD risk is single nucleotide polymorphisms in complement factor H (CFH). As such, I hope that next year we will see some research showing that inhibition of complement factors block drusen formation in certain patients," said Dr Mauget-Faysse.

            

    

    

Professor Rizzo, on the other hand, believes that we will see more and more studies advocating combination approaches to AMD therapy and the treatment of other retinopathies. He also thinks that we will see further improvements to MIVS instrumentation and techniques that allow surgeons to further reduce surgical trauma and increase patient comfort. "I also think that implants, which deliver sustained-release drug therapy for the treatment of DME will continue to yield impressive results in 2008," he hypothesized.

Dr Stefansson agrees that the benefits of combination therapies and surgery/therapeutic combinations will dominate the headlines in 2008. Meanwhile, he also hopes that studies touting the benefits of retinal oximetry will also be announced next year.

"I sincerely believe that we will see a shift from 'monotherapeutic thinking' to 'oncologic thinking' in terms of our treatment approaches. I also expect more interest in diabetic retinopathy. Dry AMD and prevention will also be a hot topic," concluded Professor Augustin.

References
1. A.J. Augustin, et al. Retina February 2007;27(2):133-140.
2. M. Inoue, et al. Am. J. Ophthalmol. November 2004;138(5):867-869.
3. G.S. Hageman et al. Prog. Retina Eye Res. 2001;20:705-732

Special contributors

                            

Prof. Dr. Albert L. Augustin             Professor Stanislao Rizzo

                            

Martine Mauget-Faysse, MD             Einar Stefansson, MD, PhD

1, 2, 3, 4, 5

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
(Image credit: Ophthalmology Times Europe) AGS 2025: Clemens Strohmaier, PhD, on improving aqueous humour outflow following excimer laser trabeculostomy
3 experts are featured in this series.
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
3 experts are featured in this series.
© 2025 MJH Life Sciences

All rights reserved.